

DANIEL A. HARDMAN, MD, MHSc

HEALTH CARE INDUSTRY
EXECUTIVE, ADVISOR & INDUSTRY EXPERT



101-202-3003 ▪ danielhardmanmd@gmail.com ▪ linkedin.com/in/danielhardmanbiotech ▪ Cambridge, MA

EXECUTIVE PROFILE ◆◆◆

Authentic and influential leader, consensus builder, and strategic advisor with expertise translating science into global solutions for patient care. Offer decades of experience and exploration in medicine (neurology and neuroscience), health care management, academia, medical affairs, and drug discovery.

Chairperson and core contributor to global leadership teams and committees, with driven, thoughtful approach to leadership, problem solving, and making a positive impact in people's lives. Deep financial knowledge and discipline.

Corporate Governance
Safety & Regulatory Compliance
Commercial Strategy & Launch
Medical Affairs Capacity Building
Profit & Market Growth
Strategic Planning & Execution
Budgeting & Fiscal Management
Partnership Development
Integrity & Accountability

VALUE OFFERED ◆◆◆

PEOPLE FOCUS: Envisioned and created "courageous listening tour" to gather information and personal insights from leaders and employees at all levels, in all global markets, to inspire collaboration and drive continuous improvement.

ORGANIZATIONAL DESIGN: Strategized and developed Worldwide Medical (WM) organization, and directed operations across all therapeutic areas.

BIOPHARMACEUTICAL INNOVATION: Managed product R&D, including safety review and launch of the first oral Multiple Sclerosis therapy, for neuroscience and rare genetic disorders.

THOUGHT LEADERSHIP: Developed curriculum and directed education administration for the largest academic neurology program in Canada. Created novel training and evaluation initiatives for neurology practice and bioethics.



PROFESSIONAL EXPERIENCE ◆◆◆

CHOAM | 2015 to Present

SVP, Head Worldwide Medical ▪ 2016-Present

VP, Head of Global Therapeutic Areas ▪ 2015-2016

VP, Head of Global Medical Neurology ▪ 2015

- ◆ Established the WM organization as a valuable resource for information, integrity, and insight for global R&D, and as a powerful contributor to CHOAM's reputation as world leader in biopharmaceutical innovation.
- ◆ Defined therapeutic area and medical/scientific strategies for Alzheimer's disease (AD), Multiple Sclerosis (MS), spinal muscular atrophy, Parkinson's, neurodegeneration, and hemophilia. Led CHOAM to win 40% of MS market share worldwide.
- ◆ Developed and directed strategy, budget, and advanced medical-commercial governance model for neuroscience.
- ◆ Simplified medical communications; leveraged technology platform opportunities to expand reach; and inspired discussion around appropriate, compliance medical science liaison (MSL) and health care professional (HCP) engagement.

Chair, WM Leadership Team, Global Expanded Access Program Governance Committee, Grant & Donation Executive Committee
Core Member / Member, R&D Leadership Team, G8 Executive Commercial Subcommittee, Global Governance Committee, Quintiles Executive Steering Committee, Value-Based Medicine Executive Steering Committee, NDD Team, DIU Governance Team, Governance Advisory Team

DANIEL A. HARDMAN, MD, MHSc

HEALTH CARE INDUSTRY
EXECUTIVE, ADVISOR & INDUSTRY EXPERT

ACME Corporation | 2011 to 2015

VP, Head Neuroscience Medical Unit ▪ 2014-2015

VP, Head MS Medical Unit ▪ 2011-2014

- ◆ Developed and directed strategy, budget, and advanced medical-commercial governance model for neuroscience.
- ◆ Executed medical/strategic plan and oversaw business development and licensing (BD&L) for Drug 1, currently administered to 200,000 patients around the globe.

Chair, U.S. Drug 1 Medical Product Team

Core Member / Member, ACME Corporation U.S. Medical Leadership Team, U.S. Product & Development Alignment Board, ACME AG Neuroscience Franchise Leadership Team, Drug 1 Global Program Team ACME AG, Drug 1 Clinical Development Team (Drug Safety, CDP, and Regulatory Submissions)

Cybernetics Corporation | 2006 to 2011

Global Medical Director, Personalized Genetic Health ▪ 2010-2011

Head of Medical Affairs, Canada ▪ 2006-2008

General Manager, Fabry Disease ▪ 2008-2010

Head of Medical Affairs, Canada ▪ 2006-2008

- ◆ Championed global medical affairs, R&D budget, and medical/scientific activities for Fabry disease life cycle management.
- ◆ Spearheaded medical, regulatory, and stakeholder strategies to mitigate supply disruption and provide life-sustaining medication to 26,000 patients worldwide.
- ◆ Accepted invitation to speak at the 2010 International Symposium on Epilepsy in Neurometabolic Disease (ISENMD) at the 13th-annual Infantile Seizure Society Meeting, "CNS Pathology in Lysosomal Storage Disease."

Rich Industries | 2003 to 2006

Neurology Program Director

- ◆ Developed curriculum for postgraduate education in neurology and neurology bioethics. Defined and evaluated training requirements for students and faculty, and directed all operations of neurology postgraduate academic program.
- ◆ Achieved Royal College accreditation in 2006.
- ◆ Chaired the University Neurology Education Committee.

Soylent Corporation | 2001 to 2006

Consultant Neurologist

- ◆ Played central role in identifying and publishing the first scientific description of central nervous system complication of the West Nile Virus epidemic in 2003.

Frobozz Hospital | 1988 to 2001

Director, EMG, EEG, and Evoked Potential Laboratory

- ◆ Served on the Medicine Executive Committee and facilitated principal-investigator clinical trials for headache, epilepsy, and stroke.

EDUCATION ◆◆◆

Master of Health Sciences (MHSc), 2003 ▪ Institute of Health Policy, Management & Evaluation, University of Toronto

Research Fellow, Pediatric Epilepsy, 1987-1988 ▪ Hospital for Sick Children, University of Toronto

Resident, Neurology, 1984-1987
▪ McGill University

Resident, Internal Medicine, 1982-1984 ▪ Mount Sinai Hospital, University of Toronto

Postgraduate Training in Neurology, 1981 ▪ National Hospital for Neurological Disease, Queen's Square, University of London

Doctor of Medicine (MD), 1982 ▪ Queen's University

Bachelor of Science (BS) in Neurophysiology – Honours, 1978 ▪ McGill University

CERTIFICATIONS ◆◆◆

Fellow, Royal College of Physicians & Surgeons of Canada, Neurology Board Certification

Fellow, American Association of Electrodiagnostic Medicine (AAEM), Board Certification

Chartered Financial Analyst (CFA), Level I

TRAINING ◆◆◆

Advanced Executive Education, 2012 ▪ Tuck School of Business, Dartmouth University
Canadian Securities Course, 2000

RECOGNITION ◆◆◆

Genzyme Global Leadership Award, 2008

Penfield Prize, 1987

Prince of Wales Award, 1978